Targeting cellular drivers and counter-regulators of hyperglycaemia- and transforming growth factor-β1-associated profibrotic responses in diabetic kidney disease

Experimental Physiology

Volumn 99, Issue 9, 2014, Pages 1154-1162

  Docherty, Neil G ^a   Murphy, Madeline ^a   Martin, Finian ^a   Brennan, Eoin P ^a,b   Godson, Catherine ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIURETIC AGENT; GLUCOSE; LIPOXIN; MICRORNA; TRANSFORMING GROWTH FACTOR BETA1; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GREM1 PROTEIN, HUMAN; IHG-1 PROTEIN, HUMAN; MIRNLET7 MICRORNA, HUMAN; PROTEIN; SIGNAL PEPTIDE;

ARTICLE; DIABETES MELLITUS; DIABETIC KIDNEY DISEASE; EPIDEMIC; EPITHELIUM CELL; FIBROSIS; GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IN VITRO STUDY; INFLAMMATORY INFILTRATE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TUMOR; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROGRESSIVE RENAL INJURY; RENAL MESANGIAL CELL; RENAL REPLACEMENT THERAPY; TUBULOINTERSTITIAL FIBROSIS; ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; KIDNEY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG DESIGN; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MICRORNAS; MOLECULAR TARGETED THERAPY; PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84908298919     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2014.078774     Document Type: Article

References (58)

1. Abdullah A, Peeters A, de Courten M & Stoelwinder J (2010). The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 89, 309-319.
2. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA & Holman RR; UKPDS Group (2003). Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63, 225-232.
3. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J & de Boer IH (2013). Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24, 302-308.
4. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R & Zeisberg M (2010). Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16, 544-550.
5. Bleyer AJ, Fumo P, Snipes ER, Goldfarb S, Simmons DA & Ziyadeh FN (1994). Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int 45, 659-666.
6. Bonventre JV (2012). Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol 32, 452-462.
7. 4 attenuate experimental renal fibrosis. FASEB J 25, 2967-2979.
8. 4 attenuates adipose inflammation. FASEB J 26, 4287-4294.
9. Brennan EP, Nolan KA, Börgeson E, Gough OS, McEvoy CM, Docherty NG, Higgins DF, Murphy M, Sadlier DM, Ali-Shah ST, Guiry PJ, Savage DA, Maxwell AP, Martin F & Godson C; GENIE Consortium (2013). Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. J Am Soc Nephrol 24, 627-637.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z & Shahinfar S; RENAAL Study Investigators (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345, 861-869.
11. Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
12. Cahill E, Costello CM, Rowan SC, Harkin S, Howell K, Leonard MO, Southwood M, Cummins EP, Fitzpatrick SF, Taylor CT, Morrell NW, Martin F & McLoughlin P (2012). Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 125, 920-930.
13. Clarkson MR, Murphy M, Gupta S, Lambe T, Mackenzie HS, Godson C, Martin F & Brady HR (2002). High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly. J Biol Chem 277, 9707-9712.
14. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM & Parikh CR (2012). Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172, 761-769.
15. Corcoran JB, McCarthy S, Griffin B, Gaffney A, Bhreathnach U, Börgeson E, Hickey FB, Docherty NG, Higgins DF, Furlong F, Martin F, Godson C & Murphy M (2013). IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-β1-induced fibrotic responses. Biochim Biophys Acta 1833, 1969-1978.
16. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA & Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31-40.
17. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Glasziou P, Grobbee DE, MacMahon S & Chalmers J; ADVANCE Collaborative Group (2009). Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20, 883-892.
18. Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, Martin F, O'Meara Y, Schmid H, Henger A, Kretzler M, Droguett A, Mezzano S & Brady HR (2005). Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 45, 1034-1039.
19. Dominguez JH, Camp K, Maianu L, Feister H & Garvey WT (1994). Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol Renal Physiol 266, F283-F290.
20. Duran-Salgado MB & Rubio-Guerra AF (2014). Diabetic nephropathy and inflammation. World J Diabetes 5, 393-398.
21. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME & Brownlee M (2008). Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205, 2409-2417.
22. Ferraris RP & Diamond JM (1989). Specific regulation of intestinal nutrient transporters by their dietary substrates. Annu Rev Physiol 51, 125-141.
23. Ford ES (2005). Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769-1778.
24. Gaede P, Lund-Andersen H, Parving HH & Pedersen O (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358, 580-591.
25. Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, Yokomizo H, Hirata E, Sonoda N & Takayanagi R (2012). GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 61, 1422-1434.
26. Hickey FB & Martin F (2013). Diabetic kidney disease and immune modulation. Curr Opin Pharmacol 13, 602-612.
27. Holman RR, Paul SK, Bethel MA, Matthews DR & Neil HA (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359, 1577-1589.
28. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D & Hramiak I; ACCORD trial group (2010). Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419-430.
29. Kato M & Natarajan R (2012). MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy. Semin Nephrol 32, 253-260.
30. Kumar PA, Chitra PS & Reddy GB (2013). Metabolic syndrome and associated chronic kidney diseases: nutritional interventions. Rev Endocr Metab Disord 14, 273-286.
31. Lakshmanan AP, Watanabe K, Thandavarayan RA, Sari FR, Harima M, Giridharan VV, Soetikno V, Kodama M & Aizawa Y (2011). Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action. Free Radic Res 45, 575-584.
32. Lan HY & Chung AC (2012). TGF-β/Smad signaling in kidney disease. Semin Nephrol 32, 236-243.
33. Li R, Zhang P, Barker LE, Chowdhury FM & Zhang X (2010). Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 33, 1872-1894.
34. McKnight AJ, Patterson CC, Pettigrew KA, Savage DA, Kilner J, Murphy M, Sadlier D & Maxwell AP; Warren 3/U.K. Genetics of Kidneys in Diabetes (GoKinD) Study Group (2010). A GREM1 gene variant associates with diabetic nephropathy. J Am Soc Nephrol 21, 773-781.
35. McMahon R, Murphy M, Clarkson M, Taal M, Mackenzie HS, Godson C, Martin F & Brady HR (2000). IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-β1. J Biol Chem 275, 9901-9904.
36. Madsbad S (2014). The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 16, 9-21.
37. Massagué J (2012). TGFβ signalling in context. Nat Rev Mol Cell Biol 13, 616-630.
38. Mather A & Pollock C (2011). Glucose handling by the kidney. Kidney Int Suppl, S1-S6.
39. Murphy M, Docherty NG, Griffin B, Howlin J, McArdle E, McMahon R, Schmid H, Kretzler M, Droguett A, Mezzano S, Brady HR, Furlong F, Godson C & Martin F (2008). IHG-1 amplifies TGF-β1 signaling and is increased in renal fibrosis. J Am Soc Nephrol 19, 1672-1680.
40. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F & Brady HR (1999). Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274, 5830-5834.
41. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD & Chang YS (2007). Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18, 1227-1238.
42. Reddy MA, Tak Park J & Natarajan R (2013). Epigenetic modifications in the pathogenesis of diabetic nephropathy. Semin Nephrol 33, 341-353.
43. Rodrigues-Diez R, Lavoz C, Carvajal G, Rayego-Mateos S, Rodrigues Diez RR, Ortiz A, Egido J, Mezzano S & Ruiz-Ortega M (2012). Gremlin is a downstream profibrotic mediator of transforming growth factor-beta in cultured renal cells. Nephron Exp Nephrol 122, 62-74.
44. Rodriguez-Iturbe B, Johnson RJ & Herrera-Acosta J (2005). Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl, S82-S86.
45. Roxburgh SA, Kattla JJ, Curran SP, O'Meara YM, Pollock CA, Goldschmeding R, Godson C, Martin F & Brazil DP (2009). Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 58, 1641-1650.
46. Roxburgh SA, Murphy M, Pollock CA & Brazil DP (2006). Recapitulation of embryological programmes in renal fibrosis - the importance of epithelial cell plasticity and developmental genes. Nephron Physiol 103, p139-p148.
47. Serhan CN (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101.
48. Sharma K, Jin Y, Guo J & Ziyadeh FN (1996). Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45, 522-530.
49. Siebel AL, Fernandez AZ & El-Osta A (2010). Glycemic memory associated epigenetic changes. Biochem Pharmacol 80, 1853-1859.
50. Vallon V (2011). The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300, R1009-R1022.
51. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC & Rieg T (2013). Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304, F156-F167.
52. Walsh DW, Godson C, Brazil DP & Martin F (2010). Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 20, 244-256.
53. Wang B, Jha JC, Hagiwara S, McClelland AD, Jandeleit-Dahm K, Thomas MC, Cooper ME & Kantharidis P (2014). Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int 85, 352-361.
54. Williams TM, Little MH & Ricardo SD (2010). Macrophages in renal development, injury, and repair. Semin Nephrol 30, 255-267.
55. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F & Kalluri R (2003). BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9, 964-968.
56. Zhang Q, Shi Y, Wada J, Malakauskas SM, Liu M, Ren Y, Du C, Duan H, Li Y, Li Y & Zhang Y (2010). In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS One 5, e11709.
57. Ziyadeh FN, Fumo P, Rodenberger CH, Kuncio GS & Neilson EG (1995). Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen α1 (IV) in glomerular mesangial cells. J Diabetes Complications 9, 255-261.
58. Ziyadeh FN, Sharma K, Ericksen M & Wolf G (1994). Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93, 536-542.